---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018205"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-09-08T23:59:59+00:00"
generated_at: "2026-06-23T13:07:53.767060+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA

## Summary
- At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.
- All-dose ORR 63.2% (24/38), confirmed ORR 57.9% (22/38), DCR 94.7%.
- 68% of patients remain on treatment; median follow-up 6 months (range <0.1-18.5).
- No grade 4/5 treatment-related AEs; most common low-grade stomatitis (48%) and PPE (46%).
- Abstract selected for oral presentation at ESMO Congress 2022 on Sept 11.

## SEC filing metadata
- accession: 0000950170-22-018205
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/0000950170-22-018205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022018205/rlay-20220907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018205
- JSON: https://secwatch.observer/filing/0000950170-22-018205.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.